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We read with interest the detailed and much-needed review and meta-analysis of analgesics on cancer 
metastasis in animal models by Hooijmans et al [4]. This is an area that is of increasing concern for 
clinicians and patients. When sub-analysed by analgesic groups, they reported a link between non-
steroidal anti-inflammatory drugs (NSAIDs) and reduced metastasis, but from the limited data 
available, opioids did not influence metastasis in animal models. It was also of interest that co-
administration of opioids abolished the benefit of reduced metastasis from NSAIDs. Most of the opioid 
experiments used morphine and, as these are a group of heterogeneous molecules with potentially 
differing effects [5], there was unfortunately not enough data to discern if there was a difference 
between opioids,  
Opioids, especially morphine, are commonly used in cancer pain management. There are two main, 
scenarios in which opioids are used in patients with cancer: 1) acute administration for surgical 
resection of cancer and 2) for chronic cancer pain management. The influence of opioids on patients 
following surgical resection of their cancer is likely to be very different to their influence on individuals 
being treated for chronic cancer pain due to differing drug regimens (including anaesthetics), the 
duration of opioid administration, immune cell activation and systemic tumour cell release [3,6].  
The non-surgical literature assessing clinical outcomes in patients with cancer prescribed opioids is 
sparse. A systematic review indicated that morphine (no studies with other opioids were identified) 
might affect aspects of immune function but did not find any studies measuring the impact of these 
immunological changes on clinical outcomes [1]. 
Although we agree that the animal data is useful to guide translational studies, clinicians need 
adequately powered studies in relevant groups of patients in order to inform clinical practice and 
optimise the care of patients with cancer. This is particularly pertinent as our own recent systematic 
review reported a possible association between long-term regular systemic opioid analgesia and 
shorter survival in adult patients with cancer [2]. However, an important limitation of research in this 
field is that the relationship between greater analgesic requirements and shorter survival is likely to 
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be mediated by painful progressive cancer. Pain control is vital and there is no definitive data 
suggesting that opioids are detrimental, thus based on current evidence opioids should continue to 
be used for cancer pain management. However, we are still lacking critical data on how to optimally 
manage pain with opioids in patients with cancer. There is a need for high-quality prospective studies 
which assess clinical endpoints such as metastasis and survival in patients with cancer on long-term 
opioids.  
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